Drug Induced Liver Injury (DILI) Conference XV: The Importance of Getting it Right
Wednesday, March 18, 2015 –
Thursday, March 19, 2015
7:30 AM – 3:30 PM
Marriott Inn & Conference Center
University of Maryland
3501 University Blvd.
East Hyattsville, Maryland 20783
How to measure and interpret DILI information and make correct diagnoses
Serious drug-induced liver injury (SDILI) is a major problem for drug development and clinical care. Key information used in detection of liver injury caused by drugs includes serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), plus total bilirubin (TBL) concentration. Time courses of changes of variables in selected patients, and a well-constructed clinical narrative help greatly. This academic-industry-government international conference will discuss new findings and thinking about DILI, including presentations by experts in clinical hepatology, toxicology, and other fields, and lively discussions with all registrants. We look forward to your participation!
Organizers: John R. Senior and Lana Pauls
The program is co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Critical Path Institute (C-Path), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The program is endorsed by the National Institutes of Health (NIH) the Drug-Induced Liver Injury Network (DILIN), and the American Association for the Study of Liver Diseases (AASLD).